5 terminated. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 5 |
| Phase 2 | 1 | Terminated 1 |
Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL - Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular | Phase 3 | Terminated | Abbott | 12 | 2009-01-01 | 2012-01-20 |
| Hypertension in Hemodialysis Patients (Aim 3) Lisinopril, Atenolol - Hemodialysis, Hypertension | Phase 3 | Terminated | Indiana University | 200 | 2005-08-01 | 2016-01-18 |
Anemia (2) · Bone Marrow Diseases (2) · Hematologic Diseases (2) · Hypertrophy, Left Ventricular (2) · Myeloproliferative Disorders (2) · Polycythemia Vera (2) · Primary Myelofibrosis (2) · Splenomegaly (2) · Thrombocythemia, Essential (2) · Thrombocytopenia (2) · Angina Pectoris (1) · Cardiomyopathies (1) · Cardiomyopathy, Hypertrophic (1) · Cardiomyopathy, Hypertrophic, Familial (1) · Dyspnea (1)
Pathological Conditions, Anatomical (5) · Pathological Conditions, Signs and Symptoms (5) · Cardiovascular Diseases (3) · Heart Diseases (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Neoplasms (2) · Cardiomegaly (2) · Cytopenia (2) · Hematologic Neoplasms (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Thrombocytosis (2)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Atenolol (1) · Lisinopril (1) · eleclazine (1) · paricalcitol (1)
CTI BioPharma (2) · Abbott (1) · Gilead Sciences (1) · Indiana University (1)
United States (5) · Australia (4) · Germany (4) · United Kingdom (4) · Czechia (3) · France (3) · Italy (3) · Netherlands (3) · Russia (3) · Belgium (2) · Hungary (2) · New Zealand (2) · Canada (1) · Greece (1) · Israel (1)
Beth Ziemba (1) · Dennis Andress, MD (1) · Rajiv Agarwal, MD (1) · Simran Singh (1)
PMID 33275766, PMID 18591942, PMID 24398888, PMID 34551507, PMID 37651553, PMID 39400386, PMID 42316774
R01DK062030 (1)